Research Article
Improved Efficacy of Transcatheter Arterial Chemoembolization Using Warmed Miriplatin for Hepatocellular Carcinoma
Table 3
Evaluation of the effect of anticancer agents on the hepatic artery.
| | | Epirubicin/cisplatin ( = 43) | Nonwarmed miriplatin ( = 30) | Warmed miriplatin ( = 46) |
| | Damage grade | | | | | 0 (no damage) | 25 (58.1%) | 22 (73.3%) | 44 (95.7%) | | 1 (irregularity) | 5 (11.6%) | 6 (20.0%) | 2 (4.3%) | | 2 (narrowing) | 1 (2.4%) | 0 (0%) | 0 (0%) | | 3 (stenosis) | 3 (7.0%) | 0 (0%) | 0 (0%) | | 4 (occlusion) | 9 (20.9%) | 2 (6.7%) | 0 (0%) | | Damage level | | | | | 1 (PHA) | 1/18 (5.6%) | 0/8 (0%) | 0/2 (0%) | | 2 (lobar branch) | 3/18 (16.7%) | 0/8 (0%) | 0/2 (0%) | | 3 (segmental branch) | 6/18 (33.3%) | 3/8 (37.5%) | 1/2 (50%) | | 4 (subsegmental branch) | 8/18 (44.4%) | 5/8 (62.5%) | 1/2 (50%) | | A-P shunt formation | | | | | Yes | 2 (4.7%) | 3 (10.0%) | 0 (0%) | | No | 41 (95.3%) | 27 (90.0%) | 46 (100%) | | Number of sessions | | | | | 1 | 28 (65.1%) | 24 (80.0%) | 27 (58.7%) | | 2 | 10 (23.3%) | 5 (16.7%) | 14 (30.4%) | | 3 | 1 (2.3%) | 1 (3.3%) | 4 (8.7%) | | 4–6 | 4 (9.3%) | 0 (0%) | 1 (2.2%) |
|
|
Data in this table were obtained from consensus of two radiologists.
PHA: proper hepatic artery; A-P shunt: arterioportal shunt.
|
